Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AC Immune SAACIU · Entity 6075 | Director | October 02, 2026 | October 09, 2026 |
| IRONWOOD PHARMACEUTICALS INCIRWD · Entity 5213 | Chief Financial Officer | February 27, 2017 | March 01, 2017 |
| Notable Labs, Ltd.NTBL · Entity 87239 | Director | May 08, 2024 | May 10, 2024 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | Chief Financial Officer | October 01, 2018 | October 02, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AC Immune SA
Report date October 02, 2026 · Filed October 09, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 12,959 |
Reported balance
Holding disclosure · report date 2026-10-02 · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · Balance 12,959 F1: Includes 8,936 common shares underlying outstanding restricted share units. |
| Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.71 · Expires 2036-10-01 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-10-02 · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · Balance Not disclosed |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 8,936 common shares underlying outstanding restricted share units.
IRONWOOD PHARMACEUTICALS INC
Report date February 27, 2017 · Filed March 01, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 42,013 |
Reported balance
After 2017-02-27 transaction · row 1
1 source rowRow 1 · 2017-02-27 · Grant · Acquired 21,250 · Balance 42,013 F1: The restricted stock unit award, granted as an annual performance award, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.77 · Expires 2027-02-27 | Direct | 127,500 |
Reported balance
After 2017-02-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-02-27 · Grant · Acquired 127,500 · Balance 127,500 F2: The option, granted as an annual performance award, vests as to 2.08333% of the shares of Class A Common Stock on each monthly anniversary of January 1, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock unit award, granted as an annual performance award, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof.
F2: The option, granted as an annual performance award, vests as to 2.08333% of the shares of Class A Common Stock on each monthly anniversary of January 1, 2017.
Notable Labs, Ltd.
Report date May 08, 2024 · Filed May 10, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 40,247 |
Reported balance
After 2024-05-08 transaction · row 1
1 source rowRow 1 · 2024-05-08 · Grant · Acquired 40,247 · Balance 40,247 F1: Grant of restricted shares vesting in two equal annual installments from the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted shares vesting in two equal annual installments from the date of grant.
VERTEX PHARMACEUTICALS INC / MA
Report date October 01, 2018 · Filed October 02, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,430 |
Reported balance
After 2018-10-01 transaction · row 1
1 source rowRow 1 · 2018-10-01 · Sale · Disposed 1,076 · Balance 12,430 F1: Transaction made pursuant to Mr. Graney's company-approved trading plan under Rule 10b5-1. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to Mr. Graney's company-approved trading plan under Rule 10b5-1.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 08, 2024 Filed May 10, 2024 17:07 UTC | Notable Labs, Ltd. NTBL · Entity 87239 | GrantOrdinary Shares | 40,247 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-009931 · form4.xml · nonDerivative · entry 1 Graney Thomas · CIK 0001618275 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,247 F1 · price: Grant of restricted shares vesting in two equal annual installments from the date of grant. Read SEC document |
| January 24, 2024 Filed Jan 26, 2024 11:04 UTC | Notable Labs, Ltd. NTBL · Entity 87239 | GrantStock Option · Derivative | 9,753 | $0.00 Strike: $1.28 | $0.00 |
DisclosureSEC source: 0001062993-24-001363 · form4.xml · derivative · entry 1 Graney Thomas · CIK 0001618275 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,753 Underlying: Ordinary Shares · 9,753 shares Expires 2034-01-24 F1 · derivative.exercise_date: Option vests 50% on the first anniversary of date of grant and thereafter in four equal quarterly installments ending on the second anniversary of the date of grant. Read SEC document |
| October 01, 2018 Filed Oct 2, 2018 20:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,076 | $193.24 | $207,926.24 |
DisclosureSEC source: 0001209191-18-053125 · doc4.xml · nonDerivative · entry 1 Graney Thomas · CIK 0001618275 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,430 F1 · kind: Transaction made pursuant to Mr. Graney's company-approved trading plan under Rule 10b5-1. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 23:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantStock Option (Right to Buy) · Derivative | 10,436 | $0.00 Strike: $155.57 | $0.00 |
DisclosureSEC source: 0001209191-18-008548 · doc4.xml · derivative · entry 2 Graney Thomas · CIK 0001618275 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,436 Underlying: Common Stock · 10,436 shares Expires 2028-02-05 F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/6/2018. Read SEC document |
| February 06, 2018 Filed Feb 8, 2018 23:23 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-008548 · doc4.xml · nonDerivative · entry 1 Graney Thomas · CIK 0001618275 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,289 F1 · shares: Restricted stock unit award that vests in three equal installments on 2/17/2019, 2/17/2020 and 2/17/2021. Read SEC document |
| January 02, 2018 Filed Jan 3, 2018 21:49 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 777 | $149.95 | $116,511.15 |
DisclosureSEC source: 0001209191-18-000968 · doc4.xml · nonDerivative · entry 1 Graney Thomas · CIK 0001618275 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,789 F1 · kind: Transaction made pursuant to Mr. Graney's company-approved trading plan under Rule 10b5-1. Read SEC document |
| September 13, 2017 Filed Sep 15, 2017 12:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 9,566 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-052901 · doc4.xml · nonDerivative · entry 1 Graney Thomas · CIK 0001618275 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,566 F1 · shares: Restricted stock unit award that vests as to 25% of the shares on December 31, 2017 and an additional 25% of the shares on each of September 30, 2018, 2019 and 2020. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 18:28 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantEmployee Stock Option (Right to Buy) · Derivative | 127,500 | $0.00 Strike: $16.77 | $0.00 |
DisclosureSEC source: 0001209191-17-016106 · doc4.xml · derivative · entry 2 Graney Thomas · CIK 0001618275 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,500 Underlying: Class A Common Stock · 127,500 shares Expires 2027-02-27 F2 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of Class A Common Stock on each monthly anniversary of January 1, 2017. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 18:28 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantClass A Common Stock | 21,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-016106 · doc4.xml · nonDerivative · entry 1 Graney Thomas · CIK 0001618275 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,013 F1 · kind: The restricted stock unit award, granted as an annual performance award, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 16:37 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 1,417 | $16.94 | $24,003.98 |
DisclosureSEC source: 0001209191-17-014370 · doc4.xml · nonDerivative · entry 2 Graney Thomas · CIK 0001618275 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,763 F3 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on March 1, 2016. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.47 to $17.41, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 16:37 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 457 | $16.94 | $7,741.58 |
DisclosureSEC source: 0001209191-17-014370 · doc4.xml · nonDerivative · entry 1 Graney Thomas · CIK 0001618275 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,180 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with the vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on March 16, 2015. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.47 to $17.41, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.